|Bid||17.83 x 1100|
|Ask||20.65 x 1200|
|Day's Range||18.92 - 19.64|
|52 Week Range||17.57 - 26.91|
|Beta (5Y Monthly)||0.89|
|PE Ratio (TTM)||16.17|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.71|
The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.
STOUGHTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company’s common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized by its Board of Directors in August 2021.
STOUGHTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences: Jefferies London Healthcare ConferenceVirtual one-on-one meetingsDate: Thursday, November 18, 2021 Piper Sandler Annual Healthcare Conference 2021Virtual fireside chatDate: Wednesday, December 1, 2021 The fireside ch